Related Experiment Video
Updated: Jun 5, 2025
Isolation of Valvular Endothelial Cells
Published on: December 29, 2010
Engineering aortic valves via transdifferentiating fibroblasts into valvular endothelial cells without using viruses
Peng Tang1, Fuxiang Wei1, Weihua Qiao2
1Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Laboratory for Cellular Biomechanics and Regenerative Medicine, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, 430074, China.
Scientists developed a new method to directly convert fibroblasts into valvular endothelial cells (VECs) without reprogramming. This technique avoids pluripotency and tumor formation, offering a safer approach for tissue-engineered heart valves.
Area of Science:
- Regenerative Medicine
- Stem Cell Biology
- Biomaterials Engineering
Background:
- Induced pluripotent stem cells (iPSCs) offer therapeutic potential but carry risks of tumorigenesis.
- Generating specific differentiated cells like valvular endothelial cells (VECs) from iPSCs remains challenging.
- Tumorigenesis risk from iPSCs hinders their in vivo applications.
Purpose of the Study:
- To develop a safe and efficient method for generating valvular endothelial cells (VECs) without pluripotency.
- To create functional tissue-engineered aortic valves using transdifferentiated cells.
- To overcome the limitations of iPSC-based therapies for cardiovascular applications.
Main Methods:
- Direct transdifferentiation of fibroblasts into induced aortic endothelial cell-like cells (iAECs) and induced valvular endothelial cell-like cells (hiVECs) using chemical and substrate cues.
- Assessment of VEC marker expression (NFATC1), functionality in vitro, and performance on decellularized aortic valves.
- In vivo grafting of hiVECs on decellularized valves in rats and teratoma formation assay in mice compared to iPSC-derived cells.
Main Results:
- Fibroblasts were efficiently transdifferentiated into iAECs and hiVECs without expressing pluripotency markers.
- Generated iAECs and hiVECs exhibited VEC-specific markers and functionality, integrating into decellularized aortic valves.
- hiVECs demonstrated stable engraftment and protein expression in vivo for 60 days and did not form teratomas, unlike iPSC-derived cells.
Conclusions:
- Direct transdifferentiation provides a safe and efficient alternative to iPSC-based methods for generating VECs.
- This approach enables the creation of functional, tissue-engineered aortic valves without viral vectors or reprogramming.
- The study presents a promising strategy for autologous tissue-engineered heart valves, mitigating tumorigenesis risks.
